Literature DB >> 33673471

Aberrant Expression of microRNA Clusters in Head and Neck Cancer Development and Progression: Current and Future Translational Impacts.

Li-Jie Li1, Wei-Min Chang2, Michael Hsiao1,3.   

Abstract

MicroRNAs are small non-coding RNAs known to negative regulate endogenous genes. Some microRNAs have high sequence conservation and localize as clusters in the genome. Their coordination is regulated by simple genetic and epigenetic events mechanism. In cells, single microRNAs can regulate multiple genes and microRNA clusters contain multiple microRNAs. MicroRNAs can be differentially expressed and act as oncogenic or tumor suppressor microRNAs, which are based on the roles of microRNA-regulated genes. It is vital to understand their effects, regulation, and various biological functions under both normal and disease conditions. Head and neck squamous cell carcinomas are some of the leading causes of cancer-related deaths worldwide and are regulated by many factors, including the dysregulation of microRNAs and their clusters. In disease stages, microRNA clusters can potentially control every field of oncogenic function, including growth, proliferation, apoptosis, migration, and intercellular commutation. Furthermore, microRNA clusters are regulated by genetic mutations or translocations, transcription factors, and epigenetic modifications. Additionally, microRNA clusters harbor the potential to act therapeutically against cancer in the future. Here, we review recent advances in microRNA cluster research, especially relative to head and neck cancers, and discuss their regulation and biological functions under pathological conditions as well as translational applications.

Entities:  

Keywords:  HNSCC; microRNA cluster; translational application

Year:  2021        PMID: 33673471      PMCID: PMC7997248          DOI: 10.3390/ph14030194

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  226 in total

1.  Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.

Authors:  Yvonne Tay; Lev Kats; Leonardo Salmena; Dror Weiss; Shen Mynn Tan; Ugo Ala; Florian Karreth; Laura Poliseno; Paolo Provero; Ferdinando Di Cunto; Judy Lieberman; Isidore Rigoutsos; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

2.  MicroRNA-1-3p inhibits the proliferation and migration of oral squamous cell carcinoma cells by targeting DKK1.

Authors:  Zhenshi Wang; Jiaolong Wang; Zhihua Chen; Kun Wang; Lianshui Shi
Journal:  Biochem Cell Biol       Date:  2017-08-01       Impact factor: 3.626

3.  MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.

Authors:  Yulin Li; Peter S Choi; Stephanie C Casey; David L Dill; Dean W Felsher
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

4.  Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells.

Authors:  Y Yan; E A Hanse; K Stedman; J M Benson; X H Lowman; S Subramanian; A Kelekar
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

5.  miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.

Authors:  Cheng-Chieh Yang; Pei-Shih Hung; Pei-Wen Wang; Chung-Ji Liu; Ting-Hui Chu; Hui-Wen Cheng; Shu-Chun Lin
Journal:  J Oral Pathol Med       Date:  2011-01-19       Impact factor: 4.253

6.  Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; R Scott Wright; David Kallend; Wolfgang Koenig; Lawrence A Leiter; Frederick J Raal; Jenna A Bisch; Tara Richardson; Mark Jaros; Peter L J Wijngaard; John J P Kastelein
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

7.  The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.

Authors:  R Banerjee; R-S Mani; N Russo; C S Scanlon; A Tsodikov; X Jing; Q Cao; N Palanisamy; T Metwally; R C Inglehart; S Tomlins; C Bradford; T Carey; G Wolf; S Kalyana-Sundaram; A M Chinnaiyan; S Varambally; N J D'Silva
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

8.  EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma.

Authors:  Juan Lu; Fei-Peng Zhao; Zengliu Peng; Meng-Wen Zhang; Shao-Xiong Lin; Bi-Jun Liang; Bao Zhang; Xiong Liu; Lu Wang; Gang Li; Wen-Dong Tian; Ying Peng; Ming-Liang He; Xiang-Ping Li
Journal:  Oncotarget       Date:  2014-11-30

9.  Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation.

Authors:  Wei-Min Chang; Yuan-Feng Lin; Chia-Yi Su; Hsuan-Yu Peng; Yu-Chan Chang; Jenn-Ren Hsiao; Chi-Long Chen; Jang-Yang Chang; Yi-Shing Shieh; Michael Hsiao; Shine-Gwo Shiah
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

Review 10.  The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease.

Authors:  E Mogilyansky; I Rigoutsos
Journal:  Cell Death Differ       Date:  2013-12       Impact factor: 15.828

View more
  1 in total

1.  MicroRNA-200a-3p and GATA6 are abnormally expressed in patients with non-small cell lung cancer and exhibit high clinical diagnostic efficacy.

Authors:  Jie Yu; Xinyun He; Chunju Fang; Haixia Wu; Lei Hu; Yingbo Xue
Journal:  Exp Ther Med       Date:  2022-02-15       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.